Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorobenzene SCHEMBL27529703 | 0.95 | MAPK14 (0.55) | MAPK13MAPK12MAPK11MAPK14PBRM1 | |
| SCHEMBL7183309 | 0.89 | SRD5A2 (0.54) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL7194395 | 0.88 | HSD17B10 (0.58) | MAPK13MAPK12MAPK11MAPK14PBRM1 | |
| SCHEMBL1149168 | 0.86 | SRD5A2 (0.60) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL6732727 | 0.86 | PBRM1 (0.55) | MAPK13MAPK12MAPK11MAPK14PBRM1 | |
| SCHEMBL11710988 | 0.85 | ALOX15 (0.52) | MAPK13MAPK12MAPK11MAPK14PBRM1 | |
| SCHEMBL7090488 | 0.85 | JAK2 (0.53) | MAPTGAASRD5A2ALOX15MEN1 | |
| SCHEMBL8309451 | 0.83 | JAK2 (0.61) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL3531609 | 0.83 | SRD5A2 (0.49) | MAPK13MAPK12MAPK11MAPK14MAPT | |
| SCHEMBL29088628 | 0.83 | MAPT (0.51) | MAPK13MAPK12MAPK11MAPK14MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106674197-A | Aurora kinase A inhibitor and preparation and application thereof | 兰州大学 | 2017-05-17 | — | — | CN | claimed |
| CN-106674197-A | Aurora kinase A inhibitor and preparation and application thereof | 兰州大学 | 2017-05-17 | — | — | CN | disclosed |
| CN-102126994-B | Benzophenone hydrazone derivative and preparation method and application thereof | SINOCHEM LANTIAN CO LTD | 2014-07-09 | — | — | CN | disclosed |
| CN-100477340-C | Composite bodies used as separators in electrochemical cells | BASF AG (DE) | 2009-04-08 | — | — | CN | disclosed |
| US-6991874-B1 | Compositions suitable for electrochemical cells | BASF AKTIENGESELLSCHAFT (DE) | 2006-01-31 | — | — | US | disclosed |
| CN-1146588-C | Compositions suitable for use in electrochemical cells | BASF | 2004-04-21 | — | — | CN | disclosed |
| US-6656971-B2 | Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions | GUILFORD PHARMACEUTICALS INC. | 2003-12-02 | — | — | US | disclosed |
| US-6632561-B1 | Particles and dual binder composed of crosslinkable and nonreactive polymers; high temperature dimensional stability; increased lithium ion conductivity | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | disclosed |
| EP-1088007-B1 | COMPOSITIONS SUITABLE FOR ELECTROCHEMICAL CELLS | BASF AG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS INC. | 2002-11-07 | — | — | US | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0849300-A1 | Polyurethanes with covalently bound photoinitiator-units | BASF AKTIENGESELLSCHAFT (DE) | 1998-06-24 | — | — | EP | disclosed |
| EP-0794953-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-17 | — | — | EP | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996016960-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
| US-4980349-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS, ANTICOAGULANTS | SANOFI (FR) | 1990-12-25 | — | — | US | disclosed |
| US-4026697-A | HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1977-05-31 | — | — | US | disclosed |
| US-3988300-A | FOR CONTROLLING BROADLEAF WEEDS AND GRASSES | AMERICAN CYANAMID COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | MAPK13 4253/4885MAPK12 3798/4885MAPK11 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.